Clinical Trial Update: Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating safety and efficacy of Efavaleukin Alfa in steroid-refractory chronic graft-versus-host disease (cGVHD) has been terminated with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Efavaleukin Alfa (efavaleukin alfa)

Snippet

Sponsor: Amgen | Conditions: Chronic Graft Versus Host Disease cGVHD | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-11-22